The Leadership Team
The ECC Leadership Team is composed of equal numbers of professionals and patients who meet weekly, via teleconference, to discuss actions, monitor progress and consider future developments of the project. Further information on the Leadership Team is given below.
Professor Peter Selby CBE FMedSci
University of Leeds, Leeds, United Kingdom
Professor Selby is a consultant physician at St James’s University Hospital and Professor of Cancer Medicine at the University of Leeds. Peter trained at King’s College Hospital, the Royal Marsden Hospital in London and at the Princess Margaret Hospital and Ontario Cancer Institute in Toronto. He moved to Leeds in 1988 and has had a number of positions including; Head of Oncology and Cancer Research, Director of the Leeds Biomedical and Health Research Centre and Director of the Leeds Institute of Molecular Medicine. From 2000-2004 he initiated and was Director of the National Cancer Research Network and from 2004-2010 he established and was Joint Director of the NIHR Clinical Research Network, providing support to clinical research within the NHS and delivering improvements in participation and the quality of research and services.
Peter’s clinical interests have covered a wide range of cancer treatments and tumour sites, most recently urological cancers and cancers of teenagers and young adults. His research programmes have included high dose chemotherapy, combination chemotherapies, biological therapies and biomarkers, psychosocial oncology and psychometrics and clinical trials. His current research programmes are in biomarker discovery and evaluation.
Professor Selby was appointed Fellow of the Academy of Medical Sciences in 1998, and awarded a CBE in 2001 for services to cancer research and cancer care. He is President of the Association of Cancer Physicians and won the Pfizer Excellence in Oncology Lifetime Achievement award in 2007. He is an Honorary Life member of the British Psychosocial Oncology Society and remains a co-investigator on patient reported outcome research into prostate cancer and chemotherapy toxicity. In 2011 he was awarded a DSc.
Peter is President of the Association of Cancer Physicians and President and Chief Executive of the European Cancer Concord (ECC).
Professor Mark Lawler
Queens University Belfast, Belfast, United Kingdom
Professor Mark Lawler is Dean of Education for the Faculty of Medicine, Health and Life Sciences and Chair in Translational Cancer Genomics in the Centre for Cancer Research and Cell Biology at Queen’s University Belfast. He has published widely in high impact international journals and has received a number of prestigious national and international awards for his research. Mark is Vice President of the European Cancer Concord (ECC), and was the architect of the European Cancer Patient’s Bill of Rights, which he helped launch on World Cancer Day 2014 in the European Parliament in Strasbourg. He has been to the forefront of a number of patient focussed cancer healthcare initiatives including “Your Health is Your Wealth” (a community based initiative addressing early diagnosis) and “Wise Up – it’s Your Life too!” (an adolescent focussed cancer initiative) and has worked with the Northern Ireland Cancer Fund for Children (NICFC) on an Art Therapy initiative for children with cancer.
Mark is the Queen’s University Belfast lead for the MRC-CRUK Funded Stratified Medicine Colorectal Cancer Consortium (S:CORT) and also leads S:CORT’s Public and Patient Involvement and Engagement Work Stream. He is a member of the Global Alliance for Genomics and Health (GA4GH) Clinical Working Group Executive and co-chair of the GA4GH Cancer Task Team and is committed to promoting a responsible but effective data sharing culture in cancer research and cancer care for the benefit of patients. Mark is Chair of the Research Working Group of the European Alliance for Personalised Medicine (EAPM) and launched their Research Roadmap for Personalised Medicine in Europe in Brussels in September 2014. He sits on a number of European Commission/European Research Council Committees in Brussels.
Professor Lawler is a member of the ECC Board.
Professor Ian Banks
European Men’s Health Forum, Brussels, Belgium
University of Leeds, Leeds, United Kingdom
Professor Banks is a retired accident and emergency doctor and general practitioner, a visiting professor in the medical school of the University of Leeds and a Visiting Professor in men’s health at the University of Ulster and honorary senior lecturer in men and cancer at Queens University Medical School and Leeds Metropolitan University. Ian is the current chair of the European Cancer Organisation (ECCO) Patient Advisory Committee (PAC and a former president of the Men’s Health Forum (England and Wales), past vice president of the International Society of Men’s Health (ISMH), past deputy editor of the Men’s Health Journal and, for six years, the medical editor for Men’s Health magazine. He was a trustee of Developing Patient Partnerships (DPP, formerly Doctor Patient Partnership) for six years. Ian is a founder member of the Self Care Forum (UK) and the official spokesman on men’s health issues for the BMA.
He was awarded the Royal Society of Public Health (RSPH) Gold Medal for public health in 2007 and, in 2012 was appointed as Professorial Fellow to the Society. Professor Banks is a member of the ECC Board.
Ms Kate Law
Consultant Advisor, ECC
Kate Law is currently the Director of the Lister Institute (a scientific grant giving body) and is also a cancer survivor. She originally trained as nurse and roles included that of research nurse at University College London, running trials evaluating Quality of Life in lung cancer patients. She then worked at Cancer Research UK for more than 20 years, latterly as Director of Clinical and Population Research. In this role she established the first patient helpline and website for the Charity and managed the strategy and budget for the clinical and population research funded by CRUK.
Kate also represented the Charity on key national and international committees, working groups and review panels including; the Royal Marsden Hospital Board of Governors and the Board of the International Rare Cancer initiative Board (with NCRI, EORTC and NCRN) and regularly acted as a media spokesperson on clinical matters.
In additional to her role at the Lister Institute, Kate is acting as an advisor to the ECC.